+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 22 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying the physical impact of Multiple Sclerosis MS from the patients perspective while providing continued access to the drug ocrelizumab. This extension study evaluates the safety and tolerability of ocrelizumab in patients previously enrolled in certain parent studies who no longer have local access to the treatment. The study is open-label and multicenter, sponsored by Hoffmann-La Roche. Participants will receive ocrelizumab at approved doses of either 600 mg via intravenous infusion or 920 mg via subcutaneous injection, following the schedule from their original parent study. Treatment will continue until the medication becomes locally available, an unacceptable safety concern arises, the participant dies, or withdraws consent. During the study, participants will be monitored for changes in physical function using patient-reported outcome measures over up to five years. Researchers will also track access to ocrelizumab, serious adverse events, adverse events leading to discontinuation, and adverse events of special interest. The study will last up to five years, with ongoing safety and tolerability assessments throughout the treatment period.

Age: 18Years +All GendersPhase 3
56 locations
L

Actively Recruiting

Researchers are studying nulliparous pregnant women who have conceived through Assisted Reproductive Technology ART to evaluate if aspirin can help prevent preterm preeclampsia and related pregnancy complications. This group is considered at higher risk for preeclampsia and perinatal issues, with a current rate of preeclampsia up to 10%. The study aims to determine if aspirin given during pregnancy reduces these risks in this specific population. Participants are randomly assigned to receive either a daily oral dose of 150 mg low-dose aspirin or a matching placebo. Treatment starts between 9 and 14 weeks of pregnancy and continues until 35 weeks and 6 days of gestation or until labor begins. The study compares outcomes between these two groups to assess the effects of aspirin. During the trial, participants will be monitored for the development of preterm preeclampsia before 37 weeks of gestation and other pregnancy outcomes such as preterm birth, cesarean delivery, postpartum hemorrhage, placental abruption, and neonatal adverse events. The study will last up to 9 months, covering the pregnancy period, with data collected to evaluate the aspirins impact on these health measures.

Age: 18Years +FEMALEPhase 3
21 locations
S

Actively Recruiting

Researchers are evaluating how the size of the bougie used during laparoscopic sleeve gastrectomy LSG affects the rate of postoperative stomach leaks, which is the most common and serious complication after this weight loss surgery. This prospective randomized trial compares the use of a larger 48-Fr bougie to standard smaller bougie sizes 34, 36, or 38 Fr to see if a bigger diameter lowers leak risk without reducing long-term weight loss. Participants will undergo laparoscopic sleeve gastrectomy using either the 48-Fr bougie or a standard care bougie. The bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach before the gastrectomy is performed alongside it. Patients do not know which bougie size they receive. This study aims to assess differences in leak rates and weight loss outcomes between the two bougie sizes. During the study, researchers will monitor participants for stomach leaks within 30 days after surgery as the primary outcome. Secondary outcomes include complications within 90 days, weight loss at 3, 6, 12, and 24 months, and quality of life up to 2 years. Participants will have follow-up visits for these assessments to track recovery, safety, and weight changes over time.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
12 locations
A

Actively Recruiting

Chronic hypertension affects 1 to 5% of women of childbearing age and can lead to serious complications during pregnancy, such as superimposed preeclampsia, placental abruption, intrauterine growth restriction, perinatal death, maternal death, or preterm delivery. This trial evaluates whether taking 150 mg of acetylsalicylic acid aspirin daily before 20 weeks of pregnancy can help prevent these complications in pregnant women with chronic hypertension. The study is a prospective randomized double-blind placebo-controlled trial conducted to provide clearer evidence on aspirins effectiveness in this specific population. Participants are randomly assigned to receive either aspirin 150 mg or a placebo once daily in the evening. The treatment starts immediately after randomization and continues until 35 weeks plus 6 days of gestation. Both the active drug and placebo are dispensed by the study centers pharmacy, and participants are given daily logs to record their treatment adherence. This design ensures careful monitoring and comparison of outcomes between the two groups. During the study, participants will undergo regular assessments of maternal and fetal health, including monitoring for preeclampsia, fetal growth, placental health, and timing of delivery. Researchers will measure a combined outcome of maternal and perinatal complications within 9 months, along with various secondary outcomes such as fetal development and child growth up to 4 years. Safety and treatment adherence are also tracked throughout. The total participation duration aligns with the pregnancy timeline, ensuring comprehensive observation of both mother and child.

Age: 18Years +FEMALEPhase 3
20 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of colchicine and non-enteric coated aspirin, alone or combined, in improving cardiovascular outcomes in high-risk adults with type 2 diabetes. This Phase 3 trial focuses on people aged 55 to 80 years who have type 2 diabetes and are at increased risk of cardiovascular events but have no prior history of coronary artery disease-related clinical events. The study aims to prevent serious heart-related problems such as heart attack, stroke, or urgent hospitalizations. Participants are randomly assigned to one of several groups receiving either colchicine 0.5 mg once daily, aspirin 40 mg non-enteric coated tablet twice daily, both, or matching placebos. Those eligible for aspirin therapy are grouped accordingly, while others ineligible for aspirin receive colchicine or placebo. The study uses a factorial design and quadruple masking to fairly evaluate the effects of these drugs over time. During the study, participants are monitored for up to 60 months for cardiovascular events including death, heart attacks, strokes, and hospitalizations for heart conditions. Cognitive function is also assessed yearly using MoCA scores. Researchers collect data on safety, adherence, and outcomes through regular follow-ups to understand how these treatments affect heart health and overall wellbeing in people with type 2 diabetes.

Age: 55Years - 80YearsAll GendersPhase 3
39 locations
S

Actively Recruiting

This research focuses on classifying genetic variants found in families with a history of hereditary cancer, especially breast and ovarian cancers. It aims to improve genetic counseling by studying the co-segregation of specific gene variants, including those in BRCA1, BRCA2, PALB2, and other genes tested in multigene panels. The study uses data from large French national databases to better understand the disease risk linked to these variants and to support clinical decision-making. Participants include index cases carrying variants of interest classified as class 3 variants of uncertain significance, class 4 likely pathogenic, or hypomorphic class 5 with intermediate effects. The study collects saliva samples from family members to test for these variants and applies statistical models to evaluate the likelihood that a variant causes disease. Genetic analyses are performed by partner laboratories, and results contribute to refining variant classification and recommendations. During the study, participants provide saliva samples for genetic testing and consent to share their data anonymously for analysis. Researchers monitor co-segregation of variants with disease in families over up to 15 years. The main outcome is the classification of selected variants based on family data, which may impact genetic counseling and clinical management. Results are shared at the group level without revealing individual test outcomes.

Age: 18Years +All GendersPhase Not Applicable
62 locations
E

Actively Recruiting

Researchers are studying the ability of an investigational drug called Zelpultide Alfa to reduce the occurrence of Bronchopulmonary Dysplasia BPD in extremely premature babies. This is a randomized, double-blind, placebo-controlled phase 2b3 study conducted at multiple centers. The study is designed in two parts Part 1 focuses on dose selection and exploratory evaluation of safety and effectiveness, while Part 2 confirms the findings using the selected dose from Part 1. In Part 1, participants will be randomly assigned to one of three groups receiving standard care plus either 4 mgkg or 6 mgkg of Zelpultide Alfa, or a placebo administered as air-sham. In Part 2, participants will be randomized to receive either the selected dose of Zelpultide Alfa with standard care or placebo with standard care. Treatments are given by intratracheal administration up to seven times, every 24 hours while the babies remain intubated. Participants will be closely monitored through the study period with assessments for the incidence of moderate to severe BPD or death by 36 weeks postmenstrual age. Other measures include ventilator-free days, oxygen use, extubation rates, survival, hospitalizations, and adverse events. Safety and immune responses will be tracked until hospital discharge or 36 weeks postmenstrual age, with follow-up continuing up to 24 months corrected age.

Age: 0Minutes - 96HoursAll GendersPhase 2Phase 3
49 locations
T

Actively Recruiting

Researchers are evaluating the effectiveness of cotrimoxazole compared to standard antibiotic therapy for treating ventilator-associated pneumonia VAP caused by Enterobacteriaceae in adult patients in intensive care units ICU. This multicenter randomized trial aims to determine if cotrimoxazole is not inferior to the best standard care in terms of survival 28 days after treatment begins. Patients with confirmed VAP and susceptibility to cotrimoxazole are included, with specific attention to those with or without septic shock and COVID-19 pneumonia. Participants are randomly assigned to receive either cotrimoxazole or standard antibiotic treatment, such as beta-lactams or fluoroquinolones, for a total of 7 days including initial empiric treatment. The antibiotic dosing and administration are adjusted based on current ICU recommendations. The treatment period can last up to 28 days or until death or ICU discharge if earlier. The study is not blinded due to variable therapies in the control group. During the study, patients are monitored daily until death, ICU discharge, or day 28 for vital signs, antibiotic use, new infections, and Clostridium difficile infection. Clinical and radiological evaluations occur at day 7, and weekly screening for multidrug-resistant bacteria is performed. Survival status is followed up to 90 days through phone or hospital interview. An independent committee reviews clinical and radiological outcomes without knowledge of treatment assignment to ensure unbiased assessment.

Age: 18Years +All GendersPhase 3
30 locations
E

Actively Recruiting

Researchers are studying women with endometriosis who need surgery because medical treatments have not relieved their pain. The study aims to evaluate if assessing pain-related complications before surgery can help identify patients who might benefit from specialized algological care. This care targets complex pain issues that may affect surgical outcomes but currently lacks a standard screening method. Participants will be randomly assigned to one of two groups one group will have pain questionnaires calculated to decide if they need a pre-surgery algology consultation, while the other group will have surgery without these calculations. If any test is positive in the assessment group, patients receive specialized pain care before surgery. Surgery is planned within a maximum of four months after randomization. During the study, participants will have their quality of life, pain levels, and satisfaction evaluated at various times up to one year after surgery. Researchers will assess pain using questionnaires and numerical scales, and examine the prevalence and determinants of complex pain syndromes. Safety and effectiveness of the testing and treatment approach will be monitored throughout the study period, which ends in December 2030.

Age: 18Years - 50YearsFEMALEPhase Not Applicable
9 locations
R

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the effect of virtual reality on reducing anxiety in women with suspected endometriosis during gynecological consultations. The study recognizes that patients often feel anxious in this situation and explores digital therapy as a method to help manage this anxiety. The trial is randomized and controlled, involving 46 patients divided into two groups, and is conducted over an 18-month inclusion period with individual participation lasting 6 months. Participants in the experimental group will receive Bliss DTX digital therapy, which uses a specialized video headset and audio headset to immerse patients in calming sound and visual programs for 13 minutes before their consultation. The control group will wait in the reception room without any intervention. Both groups will complete anxiety questionnaires before and after the consultation. Six months after the consultation, a follow-up call will collect information on compliance with endometriosis monitoring. Throughout the study, patients will be assessed using anxiety questionnaires and data collected during consultations. The primary outcome is the reduction in anxiety levels from before to after the consultation. Secondary assessments include pain experienced during the gynecological exam and satisfaction with the virtual reality device. Safety monitoring notes possible side effects such as nausea or dizziness related to the virtual reality headset. The total study duration for participants is 6 months, with data collection also at the 6-month follow-up.

Age: 18Years - 45YearsFEMALEPhase Not Applicable
1 location

1-10 of 22

1